Jonsson Comprehensive Cancer Center

Jennifer Grey to be Honored for Her Cancer Advocacy, Along with Chief Strategy & Marketing Officer for GE Healthcare Andy DeLaO and Renowned Cancer Physician-Scientist Dr. Antoni Ribas at Tower Cancer Research Foundation's 22nd Annual Tower of Hope Gala i

Retrieved on: 
星期一, 五月 6, 2024
FDA, Physics, Breast cancer, Searchlight Pictures, Wish You Were Here, Doctor of Philosophy, Politics, Medicine, Trametinib, Thyroid cancer, Season, ALL, UCLA, Cancer, Infant, Corner, Breast Cancer Research, Jonsson Comprehensive Cancer Center, Dirty Dancing, Ferris Bueller's Day Off, Sundance Film Festival, Vemurafenib, Dream, GE HealthCare, Research, MEK, BRAF, Work, Melanoma, Pembrolizumab, Tower Cancer Research Foundation, Pharmacology, University, American College, Hope, MD, Patient, De la O, Disease, Beverly Wilshire Hotel, Best Actress, Lionsgate, Cobimetinib, Radiation

The event begins at 6:00 PM at the Beverly Wilshire, A Four Seasons Hotel, 9500 Wilshire Boulevard in Beverly Hills, California.

Key Points: 
  • The event begins at 6:00 PM at the Beverly Wilshire, A Four Seasons Hotel, 9500 Wilshire Boulevard in Beverly Hills, California.
  • She most recently wrapped production on Julia Stiles' directorial debut for Lionsgate, "Wish You Were Here," opposite Kelsey Grammer.
  • DeLaO is the Chief Strategy & Marketing Officer for GE Healthcare's business focused on building care at the n-of-1 using the diagnostic gateway to precision health and care.
  • He is affiliated with multiple international cancer research associations, and is a past president of the American Association for Cancer Research.

INmune Bio Announces First Patient Dosed in a Phase 1/2 Study of INKmune™ in Patients with Metastatic Castration-Resistant Prostate Cancer

Retrieved on: 
星期二, 一月 2, 2024
Phase, Prostate cancer, Care, Immunotherapy, UCLA, Neoplasm, PSMA, Urology, Blood, Jonsson Comprehensive Cancer Center, DNA, Clinical trial, Artificial intelligence, University, CSO, Patient, Safety, Circulating tumor DNA, NK, PSA, Vaccine

“Results of immunotherapy trials for mCRPC have been disappointing,” said Professor Matt Rettig, Professor of Medicine and Urology, Medical Director of the Prostate Cancer Program at the David Geffen School of Medicine at UCLA and member of the Jonsson Comprehensive Cancer Center. “After many failures using T-cell focused immunotherapy approaches, targeting NK cells -- which are abundant in the prostate cancer tumor microenvironment -- is a promising and novel strategy. I am optimistic about the therapeutic potential of INKmune, an off-the-shelf innate immune therapy.”  Professor Rettig was deeply involved in the design of the clinical trial.  Dr. Rettig’s statements should not be construed as endorsement by the University of California.

Key Points: 
  • “After many failures using T-cell focused immunotherapy approaches, targeting NK cells -- which are abundant in the prostate cancer tumor microenvironment -- is a promising and novel strategy.
  • CaRe PC is an open label Phase I/II trial that will test up to three doses of INKmune™ in men with mCRPC.
  • The patient is followed for six months with careful study of immunologic and anti-cancer responses to INKmune™ treatment.
  • The sequential Phase I dose escalation portion will be followed by a Phase II trial that will simultaneously enroll patients in all dosing cohorts.

The Melanoma Research Foundation to Host the 2023 LA Miles for Melanoma 5K!

Retrieved on: 
星期四, 九月 21, 2023
Jonsson Comprehensive Cancer Center, Survivor, University, MRF, Dermatology, Australian Melanoma Research Foundation, Research, USC, Mile, Griffith Park, Novartis, Patient, Los, LOS, K, Vaccine, Nightclub, Pharmaceutical industry, L.A, Melanoma

LOS ANGELES, Sept. 21, 2023 /PRNewswire-PRWeb/ -- The Melanoma Research Foundation (MRF) is thrilled to announce the next event in its annual Miles for Melanoma nationwide 5K program, bringing together local melanoma patients, care partners and survivors. This year we will be hosting our annual L.A. event on Saturday, October 7, 2023, at Griffith Park at 7:30am PT. The 5k walk/race will bring together the Los Angeles-area melanoma community with a goal of raising $70,000 in support of critical melanoma research.

Key Points: 
  • The Melanoma Research Foundation (MRF) is thrilled to announce the next event in its annual Miles for Melanoma nationwide 5K program, bringing together local melanoma patients, care partners and survivors.
  • The 5k walk/race will bring together the Los Angeles-area melanoma community with a goal of raising $70,000 in support of critical melanoma research.
  • LOS ANGELES, Sept. 21, 2023 /PRNewswire-PRWeb/ -- The Melanoma Research Foundation (MRF) is thrilled to announce the next event in its annual Miles for Melanoma nationwide 5K program, bringing together local melanoma patients, care partners and survivors.
  • Miles for Melanoma 5K event here by Wednesday, October 4th, 2023, at 11:59PM PT.

INmune Bio Inc.’s Chief Scientific Officer, Mark Lowdell, Ph.D. to Present Plenary Talk at International Society of Cell & Gene Therapy

Retrieved on: 
星期三, 五月 24, 2023
ICST, David Geffen School of Medicine at UCLA, Jonsson Comprehensive Cancer Center, IL15, Failure, Gene, Prostate cancer, Half-life, ISCT, NK, Toxicity, Research, Cell, Protein, Cytokine, Cytokine release syndrome, Patient, Manuscript, Risk, Tesi, TME, Interleukin, UCLA, Urology, Phase, Phenotype, IND, Natural killer T cell, Memory, Safety, International Society, Vaccine, Cancer, List of things named after Thomas Bayes, Medicine

The Company believes this is a critical breakthrough to avoid the complications associated with cytokine therapy and obtain NK cells ideally suited for attacking cancer.

Key Points: 
  • The Company believes this is a critical breakthrough to avoid the complications associated with cytokine therapy and obtain NK cells ideally suited for attacking cancer.
  • Using high-dimensional flow cytometry to simultaneously analyze 31 cell surface proteins, the team analyzed resting NK cells, IL-15 LAK (LAK=lymphokine activated killer cells), CIML-NK and INKmune-primed (TpNK) side-by-side.
  • The data showed at least 8 clusters of NK cell types, one of which was restricted to CIML-NK and TpNK.
  • CIML-NK contains a large population of terminally activated cells with loss of spare respiratory activity, which is absent from TpNK.

INmune Bio, Inc. Announces FDA Clearance of IND Application for INKmune™, a Natural Killer Therapy, for a Phase I/II Trial in Metastatic Castration-Resistant Prostate Cancer

Retrieved on: 
星期一, 五月 8, 2023
David Geffen School of Medicine at UCLA, DNA, CT, Jonsson Comprehensive Cancer Center, PMSA, Prostate cancer, Progression-free survival, CSO, Clinical trial, Cancer, NK, Cell, Biomarker, Immunotherapy, Doctor of Philosophy, Trial of the century, MDS, Investigational New Drug, MD, Tesi, Patient, Blood, Toxic epidermal necrolysis, Neoplasm, UCLA, FDA, Prostate, Urology, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, PSA, Food, Safety, Pharmaceutical industry, Medical imaging, Medicine

BOCA RATON, Fla., May 08, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) announced today the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for INKmune™, a novel natural killer (NK) cell immunotherapy, for a Phase I/II open-label clinical trial for the treatment of metastatic Castration-Resistant Prostate Cancer (mCRPC).

Key Points: 
  • BOCA RATON, Fla., May 08, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) announced today the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for INKmune™, a novel natural killer (NK) cell immunotherapy, for a Phase I/II open-label clinical trial for the treatment of metastatic Castration-Resistant Prostate Cancer (mCRPC).
  • The Company believes this is the first NK immunotherapy trial in men with mCRPC, which affects more than 80,000 men in the U.S.
  • The trial is expected to enroll the first of 30 patients in the second half of 2023.
  • The first trial, called Laurel, is an on-going Phase I trial in patients with high risk MDS or AML.

Pfizer Chairman and CEO Dr. Albert Bourla to Keynote LABEST at UCLA Luskin Conference Center on May 25, 2023

Retrieved on: 
星期三, 四月 26, 2023
Jonsson Comprehensive Cancer Center, United Nations, Southern California Institute of Architecture, Research, Doctor of Philosophy, AstraZeneca, Biotechnology, Cancer, MD, Patient, UN, Faculty, LA, Growth, LOS, Ecosystem, UCLA, Conference, Pharmaceutical industry, Pfizer

LOS ANGELES, April 26, 2023 /PRNewswire-PRWeb/ -- UCLA Technology Development Group (UCLA TDG) announced today that Albert Bourla, Chairman and CEO of Pfizer will be a keynote speaker at the Los Angeles Bioscience Ecosystem Summit '23 (LABEST, pronounced L-A Best.). Dr. Bourla joins Daren Tang, United Nations World Intellectual Property Organization Director General (UN WIPO) who will also deliver a keynote address at the event.

Key Points: 
  • UCLA Technology Development Group announced today that Albert Bourla, Chairman and CEO of Pfizer will be a keynote speaker at the Los Angeles Bioscience Ecosystem Summit '23.
  • LOS ANGELES, April 26, 2023 /PRNewswire-PRWeb/ -- UCLA Technology Development Group (UCLA TDG) announced today that Albert Bourla, Chairman and CEO of Pfizer will be a keynote speaker at the Los Angeles Bioscience Ecosystem Summit '23 (LABEST, pronounced L-A Best.).
  • Dr. Bourla joins Daren Tang, United Nations World Intellectual Property Organization Director General (UN WIPO) who will also deliver a keynote address at the event.
  • UCLA TDG is excited to fill the UCLA Meyer and Renee Luskin Conference Center once again for the 2023 event, which will be held on May 25.

New Data Reinforce Ability of Veracyte’s Decipher Prostate Genomic Classifier To Help Identify Prostate Cancer Patients Who Would Benefit from Treatment Intensification

Retrieved on: 
星期一, 四月 17, 2023
Oncology, Health, Biometrics, Health Technology, Clinical Trials, Biotechnology, Jonsson Comprehensive Cancer Center, Probability, PSMA, PET, Prostate, NCCN, Patient, Risk, Translational research, Diagnosis, UCLA, Urology, Disease, Metastasis, Prostate cancer, Medical imaging

(Nasdaq: VCYT) announced that new data published in European Urology Oncology suggest the Decipher Prostate Genomic Classifier could help identify prostate cancer patients who have micrometastatic disease (difficult-to-detect tumor cells that extend beyond the prostate) and who may therefore benefit from systemic treatment intensification.

Key Points: 
  • (Nasdaq: VCYT) announced that new data published in European Urology Oncology suggest the Decipher Prostate Genomic Classifier could help identify prostate cancer patients who have micrometastatic disease (difficult-to-detect tumor cells that extend beyond the prostate) and who may therefore benefit from systemic treatment intensification.
  • It is the most validated prognostic biomarker for identifying metastatic disease risk among individuals with prostate cancer to help determine who may benefit from treatment intensification.
  • Accordingly, these patients would be more likely to benefit from systemic treatment intensification as compared to local therapy.
  • “These findings reinforce the evidence supporting the Decipher Prostate test’s ability to help inform treatment decision-making at initial prostate cancer diagnosis.

INmune Bio, Inc. Announces Submission of Investigational New Drug (IND) Application for INKmune™ to the U.S. Food and Drug Administration for Treatment of Metastatic Castration-Resistant Prostate Cancer

Retrieved on: 
星期一, 四月 3, 2023
David Geffen School of Medicine at UCLA, DNA, CT, Jonsson Comprehensive Cancer Center, PMSA, Prostate cancer, CSO, Royal Hallamshire Hospital, BOCA, NK, Cell, Biomarker, Immunotherapy, Investigational New Drug, Patient, Blood, TME, UCLA, FDA, Urology, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Safety, IND, PSA, Food, Disease, Pharmaceutical industry, Medical imaging, Medicine

“We believe this IND highlights the potential for INKmune™, our natural killer cell targeting immunotherapy, to treat solid tumors,” said RJ Tesi M.D., CEO of INmune Bio.

Key Points: 
  • “We believe this IND highlights the potential for INKmune™, our natural killer cell targeting immunotherapy, to treat solid tumors,” said RJ Tesi M.D., CEO of INmune Bio.
  • The goal of the trial is to define the safety of INKmune and demonstrate the ability of INKmune-primed NK cells to attack prostate cancer.
  • The results should allow us to choose the best dose of INKmune™ to move into a blinded randomized trial.
  • Given the novel nature of the treatment, the Company expects a period of consultation with the FDA prior to initiating the planned trial.

Tempus Announces Real-World Data-Driven Program to Accelerate Precision Oncology Research

Retrieved on: 
星期四, 十月 27, 2022
Technology, Research, Professional Services, Health, Data Analytics, Pharmaceutical, Science, Artificial Intelligence, Oncology, Professor, Health, Rush University Medical Center, University Hospitals Cleveland Medical Center, Cancer, Jonsson Comprehensive Cancer Center, Library, Disease, Doctor of Philosophy, FACP, Patient, Therapy, MD, Intelligence, TriHealth, Research, Program, Baylor College of Medicine, Sarcoma, Precision medicine, University, Data, Physician, Pharmaceutical industry, Tempus

Tempus, a leader in artificial intelligence and precision medicine, today announced Tempus+ , a proprietary program that powers collaborative precision oncology research through the use of real-world data.

Key Points: 
  • Tempus, a leader in artificial intelligence and precision medicine, today announced Tempus+ , a proprietary program that powers collaborative precision oncology research through the use of real-world data.
  • The Tempus platform is uniquely positioned to provide the resources necessary to create a clear path for collaborative research, said Mike Thompson, MD, PhD, Vice President of Clinical Partnerships at Tempus.
  • The institutions that are already leveraging Tempus+ have experienced the programs ability to accelerate their critical work, and we look forward to seeing it reach its full potential.
  • Tempus+ is creating a sustainable and secure infrastructure to collect and analyze the data required to foster research that can inform the future of clinical care.

Study Leveraging DEARhealth Care Management Platform for Ovarian Cancer Care Launched

Retrieved on: 
星期三, 十月 26, 2022
UCSD, Caregiver, GSK, Ovarian cancer, Health status of Asian Americans, Assistant, Woman, Patient, Prom, Jonsson Comprehensive Cancer Center, DEARhealth, Privacy, National Cancer Intelligence Network, HIV disease progression rates, Principal investigator, Mental health, University, UCLA, Software, LOS, National Cancer Institute, MD, Roswell Park Comprehensive Cancer Center, DRS, University of California, Irvine Medical Center, David Geffen School of Medicine at UCLA, Doctor of Philosophy, Health, UC, Triple, University of California, University of California, Davis, EMR, UCI, UCSF, Pharmaceutical industry, Medical device

LOS ANGELES, Oct. 26, 2022 /PRNewswire-PRWeb/ -- DEARhealth Inc., a health tech company focused on patients with a chronic condition and their continuous care management, announced today the launch of a randomized, multi-center, controlled study to assess the efficacy of DEARhealth's risk-based care management platform in improving the health of women with ovarian cancer.

Key Points: 
  • LOS ANGELES, Oct. 26, 2022 /PRNewswire-PRWeb/ -- DEARhealth Inc ., a health tech company focused on patients with a chronic condition and their continuous care management, announced today the launch of a randomized, multi-center, controlled study to assess the efficacy of DEARhealth's risk-based care management platform in improving the health of women with ovarian cancer.
  • The study "Value-Based Integrated Recommendation Software Guiding Ovarian Cancer Treatment (VIRGO2)" will be led by the University of California (UC) Cancer Consortium, a collaboration of UC's five National Cancer Institute-designated Comprehensive Cancer Centers.
  • "We're excited to embark on this important study that we hope will show the benefits of a harmonized care pathway for ovarian cancer accessible through the DEARhealth care management platform," said Dr. Daniel Hommes, MD, PhD, and Co-founder of DEARhealth.
  • DEARhealth's care management platform offers risk-based care pathway recommendation functionality with the input of data from electronic medical record (EMR) systems, to support provider teams, patients, and their caregivers in the management of chronic conditions.